
RealRate

PHARMACEUTICAL 2021

ROYALTY PHARMA

Royalty Pharma plc Rank 31 of 409





PHARMACEUTICAL 2021

ROYALTY PHARMA



Royalty Pharma plc Rank 31 of 409

The relative strengths and weaknesses of Royalty Pharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Royalty Pharma plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 189% points. The greatest weakness of Royalty Pharma plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is 148%, being 503% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	2,696,898
Cost of Goods Sold	0
Intangible Assets	28,666
Liabilities, Current	307,887
Liabilities, Non-Current	5,816,584
Other Assets	13,294,722
Other Compr. Net Income	-673,152
Other Expenses	318,950
Other Liabilities	0
Other Net Income	106,555
Property and Equipment	0
Research and Development	26,289
Revenues	2,122,353
Selling, General and Administrative Expense	181,715

Output Variable	Value in 1000 USD
Assets	16,020,286
Liabilities	6,124,471
Expenses	526,954
Stockholders Equity	9,895,815
Net Income	1,701,954
Comprehensive Net Income	1,365,378
Economic Capital Ratio	148%